Aclaris Therapeutics Stock Discussion

$Aclaris Therapeutics (ACRS.US)$ ATI-2138: Investigational oral covalent ITK/JAK3 inhibitor
● Top Line Results from Phase 2a Trial in AD Expected in June 2025: Dosing is complete in the single arm Phase 2a open-label trial of ATI-2138 designed to investigate the safety, tolerability, pharmacokinetics, efficacy, and pharmacodynamics of ATI-2138 in patients with moderate-to-severe AD. The Company expects to report top line results in June 2025. Potential target indications under consi...

$Aclaris Therapeutics (ACRS.US)$ 13 G FILLED 🚀

$Aclaris Therapeutics (ACRS.US)$
Aclaris Therapeutics: FDA Clears IND Application For Phase 1A/1B Clinical Trial Of ATI-052, Bispecific Anti-TSLP/IL-4R Monoclonal Antibody; Co. Expects To Initiate Trial In Q2

$Aclaris Therapeutics (ACRS.US)$ Reuters· 4 mins ago
Aclaris Therapeutics Secures U.S. Food and Drug Administration Ind Clearance for ATI-052, Enabling Advancement of Its Novel Bispecific Anti-Tslp/Il-4R Investigational Antibody

$Aclaris Therapeutics (ACRS.US)$ im bullish on this as it has the catalyst to go up and its still early days.

$Aclaris Therapeutics (ACRS.US)$ it drop,should I sell it?